Clinical Trial: A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06964165) titled 'A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)' on April 30.

Brief Summary: The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC). This study is a sub-study of the Master protocol -OPAL (NCT03574779)

Study Start Date: April 14, 2022

Study Type: INTERVENTIONAL

Condition: Ovarian Neoplasms

Intervention: DRUG: Niraparib

Niraparib will be ...